← Back

Pathmaker Neurosystems Inc. Named as Healthcare Semi-Finalist in Hello Tomorrow Challenge Global Start-Up Competition

Boston, MA (June 19, 2015) — PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing novel non-invasive systems for the treatment of neuromotor disorders, announced that it was named as one of five healthcare semi-finalists selected, and the only healthcare company in the U.S., to advance to the finale of the “Hello Tomorrow” Challenge, the global start-up competition, being held June 24-26.

Hello Tomorrow” is a global competition covering all major fields of technology that promotes the most innovative breakthrough technologies being developed by entrepreneurs who are taking on the most important challenges in the world today. This year, there were 3,600 proposal submitted from 90 countries.

PathMaker Neurosystems was selected as one of only five healthcare semi-finalists selected worldwide to present next week in the competition finale. “The PathMaker team is tremendously excited and honored to be invited to present as a semi-finalist at the Hello Tomorrow Challenge — and the only healthcare company from the U.S.,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “Our technology prototypes have already changed the lives of numerous patients with neuromotor dysfunction. We are committed to rapidly moving forward our pioneering non-invasive technology so that we can treat a global backlog of patients waiting for a therapy that can help them.”

PathMaker Neurosystems Inc. was founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. tsDCS is a novel modality for non-invasive neuromodulation that has only emerged within the last five years, being driven by fundamentally new understandings of spinal circuit biology made by our Company’s scientific advisors and their clinical work in treating patients with paralysis, muscle weakness and muscle tone disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.

About PathMaker Neurosystems Inc.

PathMaker Neurosystems Inc. is a clinical-stage neuromodulation company founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.

Press Contact: Don Goncalves, Tiziani Whitmyre, 781.793.9380, dgoncalves@tizinc.com